Home > Research > Publications & Outputs > Plasma neurofilament light chain


Text available via DOI:

View graph of relations

Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients

Research output: Contribution to journalJournal articlepeer-review

  • Makiko Shinomoto
  • Takashi Kasai
  • Harutsugu Tatebe
  • Masaki Kondo
  • Takuma Ohmichi
  • Masafumi Morimoto
  • Tomohiro Chiyonobu
  • Naoto Terada
  • David Allsop
  • Isao Yokota
  • Toshiki Mizuno
  • Takahiko Tokuda
Article numbere0211575
<mark>Journal publication date</mark>5/04/2019
<mark>Journal</mark>PLoS ONE
Issue number4
Number of pages13
Publication StatusPublished
<mark>Original language</mark>English


People with Down syndrome (DS) are at high risk of developing Alzheimer disease (AD) with aging. The diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients. The aims of this study were: 1) to examine whether plasma levels of NfL in DS patients are correlated with decreased adaptive behavior scores one year after sample collection, and 2) to compare plasma levels of NfL in adults with DS and an age-matched healthy control population. In this study, plasma levels of NfL in 24 patients with DS and 24 control participants were measured by the single-molecule immunoarray (Simoa) method. We observed significantly increased plasma NfL levels in the DS compared with the control group. There was a significant correlation between age and levels of plasma NfL in both groups. This age-dependent elevation was steeper in the DS compared with the control group. Moreover, elevated plasma NfL was associated with decreased adaptive behavior scores one year later, after age-adjustment. Previously reported blood-based biomarkers available in Simoa for DS, plasma total tau and phosphorylated tau, were not significantly correlated with the annual decrement of adaptive behavior scores after age-adjustment. These results suggest that plasma NfL has the potential to serve as an objective biomarker to predict dementia in adult DS patients.